Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
9.17M
-
Shares change
-
+191K
-
Total reported value, excl. options
-
$15.2M
-
Value change
-
-$99.2K
-
Put/Call ratio
-
0.55
-
Number of buys
-
34
-
Number of sells
-
-26
-
Price
-
$1.66
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q3 2023
82 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q3 2023.
Protalix BioTherapeutics, Inc. - COM (PLX) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.17M shares
.
Largest 10 shareholders include BlackRock Inc. (3.18M shares), STATE STREET CORP (760K shares), GEODE CAPITAL MANAGEMENT, LLC (700K shares), RENAISSANCE TECHNOLOGIES LLC (621K shares), GSA CAPITAL PARTNERS LLP (497K shares), NORTHERN TRUST CORP (406K shares), VANGUARD GROUP INC (281K shares), Nuveen Asset Management, LLC (262K shares), MORGAN STANLEY (199K shares), and BANK OF AMERICA CORP /DE/ (173K shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.